Genmab A/S (GMAB)

NASDAQ: GMAB · Real-Time Price · USD
21.31
+0.12 (0.57%)
May 29, 2025, 3:26 PM - Market open
0.57%
Market Cap 12.87B
Revenue (ttm) 3.23B
Net Income (ttm) 1.14B
Shares Out 63.34M
EPS (ttm) 18.36
PE Ratio 1.16
Forward PE 15.02
Dividend n/a
Ex-Dividend Date n/a
Volume 379,938
Open 21.17
Previous Close 21.19
Day's Range 21.12 - 21.42
52-Week Range 17.24 - 28.96
Beta 0.90
Analysts Buy
Price Target 39.17 (+83.81%)
Earnings Date May 8, 2025

About GMAB

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 2,682
Stock Exchange NASDAQ
Ticker Symbol GMAB
Full Company Profile

Financial Performance

In 2024, Genmab's revenue was 21.53 billion, an increase of 30.67% compared to the previous year's 16.47 billion. Earnings were 7.84 billion, an increase of 80.24%.

Financial numbers in DKK Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for GMAB stock is "Buy." The 12-month stock price forecast is $39.17, which is an increase of 83.81% from the latest price.

Price Target
$39.17
(83.81% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference

Media Release COPENHAGEN, Denmark; May 27, 2025 Genmab A/S (Nasdaq: GMAB) announced today that its C hief F inancial O fficer Anthony Pagano will participate in a fireside chat at the 4 6 th Goldman ...

2 days ago - GlobeNewsWire

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; May 26, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million share...

3 days ago - GlobeNewsWire

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the ...

6 days ago - Business Wire

Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference

Media Release COPENHAGEN, Denmark; May 21, 2025 Genmab A/S (Nasdaq: GMAB) a nnounced today that its Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 2025 Jefferie...

8 days ago - GlobeNewsWire

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; May 20, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 1,746 shares as a consequence of the exercise of employee warrants. The increase i...

9 days ago - GlobeNewsWire

Genmab A/S: Transitioning From Royalty Model To Commercial-Stage Oncology

Genmab has promising proprietary antibody platforms and partnerships that have helped it transition from licensor to commercial-stage biotech. Their robust royalty stream from Darzalex and Kesimpta fu...

10 days ago - Seeking Alpha

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it will present 14 abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneou...

15 days ago - Business Wire

Genmab Announces Financial Results for the First Quarter of 2024

May 8, 2025 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025

21 days ago - GlobeNewsWire

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food a...

27 days ago - Business Wire

Genmab's Outlook Beyond Darzalex's Patent Cliff

Genmab presents a long-term investment opportunity, but uncertainties around Darzalex's pending patent expiration warrant a cautious approach. The company's robust late-stage pipeline could offset DAR...

6 weeks ago - Seeking Alpha

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Company Announcement Net sales of DARZALEX ® in the first quarter of 2025 totaled USD 3,237 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen B...

6 weeks ago - GlobeNewsWire

Genmab A/S Share Capital Reduction

Company Announcement COPENHAGEN, Denmark; April 10, 2025 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S' Annual General Meeting on March 12, 2025, it was decided to reduce the Company's share capital with ...

7 weeks ago - GlobeNewsWire

Transactions In Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; April 7, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shar...

7 weeks ago - GlobeNewsWire

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Company Announcement COPENHAGEN, Denmark; April 1, 2025 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, thi...

2 months ago - GlobeNewsWire

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Media Release COPENHAGEN, Denmark; March 31, 2025 TIVDAK ® is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or ...

2 months ago - GlobeNewsWire

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; March 31, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million sha...

2 months ago - GlobeNewsWire

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S'  GMAB Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or after cancer c...

2 months ago - Benzinga

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Media Release COPENHAGEN, Denmark; March 27, 2025 TIVDAK ® is the first and only antibody-drug conjugate (ADC) approved for patients with advanced or recurrent cervical cancer in Japan Approval is bas...

2 months ago - GlobeNewsWire

Genmab Announces Initiation of Share Buy-Back Program

Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total value of DKK 4.0 billion Reduce the capital of Genmab and honor our commitments under the Restricted Stock Un...

2 months ago - GlobeNewsWire

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle) Genmab categorically refutes allegations and will vigorously...

2 months ago - GlobeNewsWire

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S®), an investigational fola...

2 months ago - Business Wire

Genmab: GEN3014's Demise And Implications For The HexaBody Platform

Genmab's stock fell after J&J opted out of developing GEN3014 due to its undifferentiated efficacy and worse safety and tolerability compared to Darzalex. Genmab wisely chose not to pursue GEN3014 fur...

2 months ago - Seeking Alpha

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, th...

2 months ago - GlobeNewsWire

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; March 12, 2025 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S' Annual General Meeting held on March 12, 2025, the Company's Board of Directors met to consti...

2 months ago - GlobeNewsWire

Passing of Genmab A/S' Annual General Meeting

Company Announcement At Genmab A/S' Annual General Meeting held today March 12, 2025, the Annual Report for 2024 was approved Discharge was given to the Board of Directors and the Executive Management...

2 months ago - GlobeNewsWire